KR102538370B1 - 안과용 현탁액 조성물 - Google Patents

안과용 현탁액 조성물 Download PDF

Info

Publication number
KR102538370B1
KR102538370B1 KR1020177023453A KR20177023453A KR102538370B1 KR 102538370 B1 KR102538370 B1 KR 102538370B1 KR 1020177023453 A KR1020177023453 A KR 1020177023453A KR 20177023453 A KR20177023453 A KR 20177023453A KR 102538370 B1 KR102538370 B1 KR 102538370B1
Authority
KR
South Korea
Prior art keywords
ophthalmic
weight
formulation
ophthalmic suspension
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177023453A
Other languages
English (en)
Korean (ko)
Other versions
KR20170105610A (ko
Inventor
모하나드 샤워
에릭 필립스
마틴 제이. 코피
Original Assignee
보오슈 앤드 롬 인코포레이팃드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55359733&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102538370(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 보오슈 앤드 롬 인코포레이팃드 filed Critical 보오슈 앤드 롬 인코포레이팃드
Publication of KR20170105610A publication Critical patent/KR20170105610A/ko
Application granted granted Critical
Publication of KR102538370B1 publication Critical patent/KR102538370B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • Y10S514/912—

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020177023453A 2015-01-26 2016-01-26 안과용 현탁액 조성물 Active KR102538370B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562107696P 2015-01-26 2015-01-26
US62/107,696 2015-01-26
PCT/US2016/014872 WO2016123079A1 (en) 2015-01-26 2016-01-26 Ophthalmic suspension composition

Publications (2)

Publication Number Publication Date
KR20170105610A KR20170105610A (ko) 2017-09-19
KR102538370B1 true KR102538370B1 (ko) 2023-06-01

Family

ID=55359733

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177023453A Active KR102538370B1 (ko) 2015-01-26 2016-01-26 안과용 현탁액 조성물

Country Status (15)

Country Link
US (3) US10596107B2 (https=)
EP (5) EP3470059B1 (https=)
JP (1) JP2018507252A (https=)
KR (1) KR102538370B1 (https=)
CN (1) CN107427464B (https=)
AU (4) AU2016211745A1 (https=)
BR (1) BR112017016016B1 (https=)
CA (1) CA2975106A1 (https=)
ES (5) ES2966595T3 (https=)
HU (5) HUE071679T2 (https=)
MX (1) MX390671B (https=)
PL (5) PL3721868T5 (https=)
PT (3) PT4268850T (https=)
SI (1) SI4268850T1 (https=)
WO (1) WO2016123079A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3470059B1 (en) 2015-01-26 2020-04-01 Bausch & Lomb Incorporated Ophthalmic suspension composition
CA3001955C (en) 2015-10-16 2023-11-28 Sun Pharma Advanced Research Company Limited Ophthalmic solution of difluprednate
EP3245988B1 (en) 2016-05-18 2023-12-27 Sonikure Holdings Limited System for ultrasound-enhanced transscleral delivery of drugs
US11344562B2 (en) 2017-08-15 2022-05-31 Nephron Pharmaceuticals Corporation Aqueous nebulization composition
EP3853317A4 (en) * 2018-09-21 2022-06-22 PS Therapy Ltd. Artificial tear, contact lens and drug vehicle compositions and methods of use thereof
JP6994061B2 (ja) * 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
EP4431497A1 (en) * 2019-02-15 2024-09-18 Bausch + Lomb Ireland Limited Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile and formulations thereof
US20230172946A1 (en) * 2019-08-18 2023-06-08 Iview Therapeutics, Inc. In-situ Gel Forming Ophthalmic Formulations Containing Difluprednate
KR102271247B1 (ko) * 2020-11-04 2021-06-30 삼천당제약주식회사 안과용 현탁액 조성물의 제조방법
CN115887372A (zh) * 2022-10-25 2023-04-04 苏州欧康维视生物科技有限公司 丙酸氟替卡松混悬液及其制备方法
CN115554238A (zh) * 2022-10-25 2023-01-03 苏州欧康维视生物科技有限公司 眼用混悬液及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050182039A1 (en) * 2004-02-13 2005-08-18 Bausch & Lomb Incorporated Use of Loteprednol etabonate for the treatment of dry eye
US20100004225A1 (en) * 2008-06-18 2010-01-07 Otonomy, Inc. Controlled release aural pressure modulator compositions and methods for the treatment of otic disorders

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4996335A (en) 1980-07-10 1991-02-26 Nicholas S. Bodor Soft steroids having anti-inflammatory activity
US4540930A (en) 1983-09-12 1985-09-10 Wisconsin Alumni Research Foundation Plywheel-powered mobile X-ray apparatus
EP0163696B1 (en) 1983-11-14 1992-11-25 Columbia Laboratories, Inc. Use of a bioadhesive
NZ226171A (en) 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
US5192535A (en) 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
IE63392B1 (en) 1988-02-08 1995-04-19 Insite Vision Inc Ophthalmic suspensions
US5124154A (en) 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5252318A (en) 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
CA2134376C (en) 1993-12-20 2001-10-23 Haresh G. Bhagat Combinations of polymers for use in physiological tear compositions
AU684115B2 (en) * 1993-12-27 1997-12-04 Mitsubishi Chemical Corporation Ophthalmic suspension containing diflupredonate
GB9718568D0 (en) * 1997-09-03 1997-11-05 Chauvin Pharmaceuticals Limite Compositions
TWI227143B (en) 1999-12-15 2005-02-01 Guo-Jiun Sung In situ gel formation for ophthalmic delivery by combining Pluronic/Carbopol medic composition and its preparing method
AR033151A1 (es) * 2001-04-12 2003-12-03 Sucampo Pharmaceuticals Inc Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares
US7001615B1 (en) 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
EP2283864A1 (en) * 2002-07-16 2011-02-16 Elan Pharma International Ltd. Liquid dosage compositions fo stable nanoparticulate active agents
CA2839847C (en) * 2003-06-13 2016-03-15 Masood A. Chowhan Ophthalmic compositions containing a synergistic combination of two polymers
US20050197303A1 (en) 2003-10-31 2005-09-08 Bausch & Lomb Incorporated Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
TWI358290B (en) 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
US7919483B2 (en) 2005-06-24 2011-04-05 Medicis Pharmaceutical Corporation Method for the treatment of acne
WO2007058935A2 (en) 2005-11-14 2007-05-24 Bausch & Lomb Incorporated Ophthalmic composition for dry eye therapy
US20100234336A1 (en) 2005-11-14 2010-09-16 Erning Xia Ophthalmic Compositions
US20120028947A1 (en) 2005-11-14 2012-02-02 Erning Xia Ophthalmic Compositions
US8501800B2 (en) 2009-03-05 2013-08-06 Insite Vision Incorporated Controlled-release ophthalmic vehicles
CN101966143A (zh) 2009-07-28 2011-02-09 胡容峰 加替沙星温度及pH敏感眼用凝胶的制备与应用
PH12012501111A1 (en) 2009-12-03 2016-09-09 Novartis Ag Carboxyvinyl polymer-containing nanoparticles suspensions
KR20140069210A (ko) 2011-09-22 2014-06-09 보오슈 앤드 롬 인코포레이팃드 안과적 겔 조성물
JP6360039B2 (ja) 2012-05-03 2018-07-18 カラ ファーマシューティカルズ インコーポレイテッド 複数の被覆された粒子を含む組成物、医薬組成物、医薬製剤、及び当該粒子の形成方法
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
CN111700879A (zh) 2012-05-03 2020-09-25 卡拉制药公司 显示提高的粘膜转移的药物纳米粒子
US8765725B2 (en) * 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
EP2847207B1 (en) 2012-05-08 2019-03-27 Nicox Ophthalmics, Inc. Fluticasone propionate nanocrystals
WO2013169458A1 (en) 2012-05-11 2013-11-14 Bausch & Lomb Incorporated Pharmaceutical compositions and methods for treating, controlling, ameliorating, or reversing conditions of dry eye
BR112014028431B1 (pt) 2012-05-11 2022-01-11 Activus Pharma Co., Ltd Nanopó de composto orgânico, método para produzir o mesmo e suspensão
MX2015002208A (es) 2012-08-31 2015-05-08 Bausch & Lomb Composiciones oftalmicas con acidos grasos omega-3.
US20150190407A1 (en) 2014-01-07 2015-07-09 Insite Vision Incorporated Methods for treatment of postoperative inflammation with reduced intraocular pressure
CN106535943A (zh) 2014-07-11 2017-03-22 富士胶片株式会社 眼科用水性组合物
NZ728136A (en) 2014-07-11 2017-10-27 Fujifilm Corp Method for producing aqueous ophthalmic composition, and aqueous ophthalmic composition
EP3179982B1 (en) 2014-07-28 2023-07-19 Sun Pharma Advanced Research Company Ltd Method of increasing bioavailability and/or prolonging ophthalmic action of a drug
EP3470059B1 (en) * 2015-01-26 2020-04-01 Bausch & Lomb Incorporated Ophthalmic suspension composition

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050182039A1 (en) * 2004-02-13 2005-08-18 Bausch & Lomb Incorporated Use of Loteprednol etabonate for the treatment of dry eye
US20100004225A1 (en) * 2008-06-18 2010-01-07 Otonomy, Inc. Controlled release aural pressure modulator compositions and methods for the treatment of otic disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Lisa Schopf et al., Ophthalmology and Therapy, 2014, vol. 3, pp.63-72

Also Published As

Publication number Publication date
AU2023248145B2 (en) 2025-08-28
US20200214977A1 (en) 2020-07-09
EP3250185A1 (en) 2017-12-06
WO2016123079A1 (en) 2016-08-04
PL3470059T3 (pl) 2020-11-30
HUE071679T2 (hu) 2025-09-28
PL3250185T3 (pl) 2019-05-31
AU2021203027B2 (en) 2023-07-13
ES3031414T3 (en) 2025-07-08
HUE059639T2 (hu) 2022-12-28
AU2016211745A1 (en) 2017-08-31
BR112017016016B1 (pt) 2023-12-19
PL3721868T3 (pl) 2022-11-07
CN107427464B (zh) 2022-04-05
PT4082531T (pt) 2023-12-14
PT4268850T (pt) 2025-06-04
JP2018507252A (ja) 2018-03-15
PL3721868T5 (pl) 2025-12-22
EP4082531A1 (en) 2022-11-02
PL4082531T3 (pl) 2024-04-08
BR112017016016A2 (pt) 2018-03-20
PL4268850T3 (pl) 2025-08-04
EP3250185B1 (en) 2018-12-05
CN107427464A (zh) 2017-12-01
EP3470059A1 (en) 2019-04-17
ES2924645T3 (es) 2022-10-10
US20160213609A1 (en) 2016-07-28
US11534395B2 (en) 2022-12-27
HUE048564T2 (hu) 2020-08-28
MX2017009699A (es) 2017-10-23
EP4268850A1 (en) 2023-11-01
EP3470059B1 (en) 2020-04-01
HUE041945T2 (hu) 2019-06-28
EP4268850B1 (en) 2025-04-16
CA2975106A1 (en) 2016-08-04
ES2966595T3 (es) 2024-04-23
PT3721868T (pt) 2022-08-12
ES2924645T5 (en) 2025-12-15
EP3721868A1 (en) 2020-10-14
KR20170105610A (ko) 2017-09-19
AU2023248145A1 (en) 2023-11-02
US20230140895A1 (en) 2023-05-11
EP4082531B1 (en) 2023-10-11
ES2787039T3 (es) 2020-10-14
HUE066045T2 (hu) 2024-07-28
EP3721868B1 (en) 2022-06-01
MX390671B (es) 2025-03-21
EP3721868B2 (en) 2025-09-03
AU2021203027A1 (en) 2021-06-10
US10596107B2 (en) 2020-03-24
US12589069B2 (en) 2026-03-31
AU2025271194A1 (en) 2025-12-18
SI4268850T1 (sl) 2025-07-31
ES2704125T3 (es) 2019-03-14

Similar Documents

Publication Publication Date Title
US12589069B2 (en) Ophthalmic suspension composition
HUE025838T2 (en) Carboxyvinyl polymer-containing nanoparticle suspensions
EP4652999A2 (en) Liquid depot for non-invasive sustained delivery of agents to the eye
EP2758031A1 (en) Ophthalmic gel compositions
HK40082997B (en) Ophthalmic suspension composition
HK40101668A (en) Ophthalmic suspension composition
HK40101668B (en) Ophthalmic suspension composition
HK40082997A (en) Ophthalmic suspension composition
HK40037317B (en) Ophthalmic suspension composition
HK40037317A (en) Ophthalmic suspension composition
US20130079315A1 (en) Ophthalmic Gel Compositions

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601